The genetic architecture of type 2 diabetes (T2D, MIM:125853) in Africa remains largely understudied. While the reduced linkage disequilibrium (LD) characteristic of African populations was used to refine and fine map the original TCF7L2 genetic association 1,2 , genome-wide and/or high throughput studies of the genetics of T2D in Africa remain limited to a genome-wide linkage analysis 3 and a large-scale replication study 4 , both from the Africa America Diabetes Mellitus (AADM) Study. African American populations, on the other hand, have been studied more comprehensively including several genome-wide association studies (GWAS) and meta-analysis of GWAS 5 . However, African American populations should not be used as proxies for populations in Africa because of differences in genetic (African Americans have ~ 20% European admixture) as well as non-genetic risk factors (including lifestyle and behavioral factors). Therefore, despite the advances over the last decade in our understanding of the role of genetic variants influencing T2D risk and the identification of the role of the genes in pathophysiology, data from Africa remains scarce.
In the present study, we conducted a GWAS of T2D in Africa using data from over 5,000
Africans enrolled from Nigeria, Ghana and Kenya as part of the Africa America Diabetes Mellitus (AADM) study 3, 6 and extend the transferability of previously reported T2D loci in Africa.
We identified a novel genome-wide significant locus for T2D -the Zinc Finger RANBP2-Type Containing 3 (ZRANB3) gene. Functional studies of the ZRANB3 ortholog in zebrafish showed that knockdown of the gene leads to reduction in beta cell number in the developing embryo.
Our findings represent an advance in our knowledge of the genetics of T2D in sub-Saharan Africa.
Results

Characteristics of discovery sample
The characteristics of the 5231 AADM study participants (2,342 T2D cases and 2,889 controls)
are shown in Table 1 . T2D cases were older than controls (mean age 55 years versus 46 years). Mean BMI was similar between cases and controls. However, cases had a significantly bigger waist circumference than controls (mean 93.7 cm versus 88.5 cm). Fasting glucose values indicate that most of the T2D cases were uncontrolled at the time of enrolment with a median fasting glucose of 153 mg/dl (8.5 mmol/L) and more than three-quarters having fasting glucose values greater than 109 mg/dl (6.1 mmol/L) at the time of enrollment into the study.
Discovery genetic association analysis
The distribution of association statistics for the genome-wide association analysis is shown in the Manhattan plot ( Figure 1 ). There was minimal inflation of the association statistics (λ = 1.013, Supplementary Figure S2 ). Three genome-wide significant loci were identified (Table 2) :
TCF7L2 (lead SNP rs7903146, T allele frequency=0.331, p=7.288 X 10 -13 ), HMGA2 (lead marker rs138066904, deletion frequency=0.096, p=2.516 X 10 -9 ) and ZRANB3 -Zinc Finger RANBP2-Type Containing 3 (lead SNP chr2:136064024, T allele frequency=0.034, p=2.831X10 -9 ). TCF7L2 is an established T2D risk locus and the lead SNP of TCF7L2 (rs7903146) in the present study is the same lead SNP reported in most GWAS of T2D to date ( Figure 2 ). HMGA2 is also a known T2D locus in both Europeans and African Americans.
However, the genome-wide significant HMGA2 variant in the present study is a deletion (CCTAG/C), not a SNP like other HMGA2 markers that have previously been found to be genome-wide significant for T2D in Europeans (leading SNP rs2258238, 68.5 kb away from the deletion) and in African Americans (leading SNP rs343092, 38.6 kb away). The LD between the deletion and these other SNPs is low (r 2 0.052 and 0.003, respectively) in this study of sub-Saharan Africans.
Replication and Annotation of ZRANB3
ZRANB3 is a novel candidate locus for T2D as it has not been previously reported in relation to T2D. The leading SNPs have a frequency of 3.6% and 6.9%, respectively (Table 3) . Of the top four markers in ZRANB3, three appear to be African-specific as they are not present in other populations as evaluated through the 1000 Genomes and gNOMAD databases. One marker (ZRANB3 2:136019729, rs755264566) is present in the gNOMAD database with an overall frequency of 5.5%. For evaluation of replication of ZRANB3 in another African ancestry population, we examined these variants in South African Zulu T2D cases and controls from the Durban Diabetes Case-Control Study (DCC) and the Durban Diabetes Study (DDS) - Table 3 .
The leading SNPs in ZRANB3 in AADM each showed consistency of direction of effect in the Zulu GWAS, despite the latter study showing lower effect allele frequencies (chr2:136064024:
T allele frequency 0.9% Zulu versus 3.4% AADM; chr2:136019729 A allele frequency 2.6%
Zulu versus 6.9% in AADM). The combined p-values for the two leading SNPs across the discovery and replication samples remained genome-wide significant (Table 3) .
ZRANB3 is a protein-coding gene with nucleic acid binding and endonuclease activity. The ZRANB3 transcript is the target of nonsense mediated decay (NMD) and is expressed in tissues relevant to T2D including adipose tissue, skeletal muscle, pancreas and liver (Supplementary Figure S3) . We identified haplotype blocks around the two genome-wide significant ZRANB3 SNPs and identified 35 and 43 target genes, respectively, from the significant trans-eQTL-gene associations in each haplotype block using the Framingham Heart Study (FHS) eQTL database (Table 4) . We also identified five common target genes for ciseQTLs in addition to ZRANB3. Overlaying these associations with known T2D loci from the Table S1 ). Of the two loci first reported in an African ancestry GWAS meta-analysis for T2D (the MEDIA Consortium), we found exact replication for INS-IGF2 rs3842770 (p=1.867 X 10 -3 , Table 4 ) but no evidence for replication for HLA-B rs2244020 (rs74995800, p=0.798).
Meta-analysis with African ancestry populations and trans-ethnic meta-analysis
We conducted an African ancestry T2D meta-analysis that included this GWAS and an African Trans-ethnic meta-analysis of the above African ancestry studies with a large GWAS of European ancestry individuals (the DIAGRAM meta-analysis of type 2 diabetes (T2D) based on the GoT2D integrated haplotypes) 8 revealed multiple genome-wide significant loci as expected. However, they are all known loci and none is a novel locus for T2D (data not shown).
Suppression of zranb3 in zebrafish results in reduced β-cell mass
To examine a potential role for zranb3 in T2D etiology in vivo we targeted the gene in transgenic zebrafish larvae in which β-cells could be visualized and quantified, Tg(insa:mCherry) 9 . Transgenic embryos were injected at the one-to two-cell stage with a morpholino (MO) designed to disrupt splicing of the endogenous zranb3 transcript at exon 5.
We first validated the efficacy of the MO to significantly suppress zranb3 mRNA expression without inducing off-target toxicity by assessing transcript levels of endogenous zranb3 and by examining the presence of a marker of MO-induced toxicity, the delta113 isoform of p53, 10 respectively (Supplementary Figure S5) . We cultured injected embryos to 5 days post fertilization (dpf) when the zebrafish principal islet is fully formed and functional and we could quantify β-cell number. Suppression of zranb3 expression resulted in a significant reduction of 
Integrative analysis of AADM discovery GWAS with transcriptomic data
Integrative analysis that combines GWAS summary statistics with eQTL data was performed to identify potential new candidate genes. The most significant genes are shown in Figure 4 .
Nearly all of these genes are not known T2D risk loci with the exception of MARCH1 which has been reported to be associated with T2D 11 . LIPC which is associated with closely related phenotypes, including the metabolic syndrome 12 and circulating levels of total cholesterol, HDL-cholesterol and triglycerides in multiple studies.
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Discussion
The vast diversity of genetic characteristics and environments across the world indicates that common complex disorders such as T2D need to be studied in diverse global populations.
Nowhere is this truer than in sub-Saharan Africa, which is not only the cradle of humanity but is also home to a vast diversity of populations with widely divergent lifestyle, behavioral and environmental factors including long term exposure to pathogens that have shaped the genomic architecture of African peoples. In the present study, we report a genome-wide analysis of T2D in over 5,000 sub-Saharan Africans representing the largest sample size from a single diabetes association study from the continent to date. Reassuringly, TCF7L2
rs7903146 was genome-wide significant as expected from previous T2D studies in Africa 4, [20] [21] [22] [23] [24] [25] and consistent with the findings of most populations studied around the world. We also replicated several previously reported T2D loci. Using exact replication strategies (same SNP, consistent direction of effect, p value < 0.05), we demonstrated that 15% of the reported loci were significantly associated in this study of sub-Saharan Africans. This is consistent with our estimates of the power of our study to replicate known loci considering effect allele frequencies and reported effect sizes. Using local replication strategies, which help to identify significant loci which would otherwise have been missed because of allele frequency and/or LD differences between populations, we replicated additional sixteen loci (i.e. significant p value in a SNP in LD with the original reported SNP). These findings extend our previous studies of transferability of T2D loci in sub-Sharan Africa. 4 Notably, the present study's exact replication rate of 15% is marginally more than the 11% that we previously reported in a smaller sample from the same study. While this difference is not statistically significant (p=0.369, test of difference between proportions), it suggests that larger sample sizes may lead to increased numbers of replicated variants because of increased statistical power. It should be noted that transferability of reported T2D genome-wide significant variants between populations has always been demonstrable for a relatively small fraction of all such loci, especially with African ancestry populations. 26, 27 . Perhaps this is not unexpected given that transferability is affected by several factors including sample sizes, effect allele frequencies, LD structure and genetic architecture of the trait. While acknowledging that increased sample size is just one of these variables, an appreciation of the final set of consistently replicable variants across populations will probably become possible when sample sizes (and the resultant statistical power) in nonEuropean studies begin to approach those of European GWAS.
A notable finding in the present study is the identification of a promising novel locus (ZRANB3:
Zinc Finger RANBP2-Type Containing 3) for T2D. Two intronic SNPs in the gene were genome-wide significant and the direction of effect was consistent for the top four SNPs in a 33 . IL23R/IL12RB2 is a known GWAS locus for age of onset of T2D 34 while variants in SLC44A4 have been implicated in the interaction between T2D and iron status biomarkers. 35 Variants in MCM6 and DARS were recently shown to be associated with total cholesterol change in response to fenofibrate in statin-treated T2D. 36 Our functional assays in zebrafish focused on the role of the ZRANB3 ortholog in the pancreas, one of the key tissues in T2D. Knockdown of the gene led to reduced zranb3 expression and to reduction in pancreatic beta cell number in the developing organism. These observations are consistent with recent evidence suggesting that Zranb3 is highly expressed in replicating murine beta cells, 37 suggesting a likely critical role of the gene in production or maintenance of beta-cells. While we found an increased ER stress in the knockdown model, this observation may be due to general stress from loss of the gene given the role of zranb3 as a mediator of DNA replication. These findings in combination with the eQTL findings suggest that the ZRANB3 locus may act directly, through other loci that it regulates (e.g. DGKB,
GTF3AP5-AGMO, IL23R/IL12RB2) or in combination with those loci to produce the pathophysiological changes that lead to altered glucose metabolism and T2D.
Integrative analysis of GWAS and transcriptomic studies are increasingly being utilized to identify novel candidate genes which may not have been detected through either type of study alone as illustrated by loci above the null line and towards the upper right quadrant of Figure   5b . We utilized this approach to generate new leads for further studies. We found some candidate genes of which two (MARCH1 and LIPC) are established T2D-related loci. The fact that they were not significant in our study indicates that integrative analysis can boost the capacity of a GWAS to identify and/or prioritize loci for further study. One of the major drawbacks of this type of integrative analysis is the relatively small sample sizes of most transcriptomic datasets 38 , which limits the power of the eQTL studies. However, this limitation would gradually diminish as more data is generated.
The identification of a novel candidate T2D locus in the present study provides further support for the notion that genome analysis studies in diverse global populations have the potential to discover novel risk loci and improve our knowledge of the genetic architecture of many common complex disorders. [39] [40] [41] [42] [43] For T2D, this has been demonstrated in studies which identified SLC6A11 in Mexicans by the SIGMA Type 2 Diabetes Consortium 44 , SGCG in Punjabi Sikhs 45 and KCNQ1 in East Asians 46,47 as novel risk loci for T2D. In the search for novel loci, this strategy of including populations of different ancestries complements the strategy of increasing sample sizes to boost statistical power to detect small effect sizes.
The present study addressed discovery science in the context of under-represented populations in genomic research, partly in response to the lack of diversity and predominance of European ancestry populations in genomic studies. 40, 42, [48] [49] [50] Several examples now exist for how lack of diversity in genomic studies is resulting in missed opportunities for discoveries and for more robust understanding of heterogeneity in effect sizes across ethnic groups. A recent example from the Population Architecture using Genomics and Epidemiology (PAGE) study demonstrated that one-quarter of genetic associations in the NHGR-EBI GWAS Catalog show significant heterogeneity in effects sizes between ethnicities. 51 Given that effect sizes are estimates of risk, this implies that risk prediction would vary substantially depending on the ethnic group. It is important to recognize that the effects of this lack of diversity extend beyond discovery science to translational studies because the resulting gaps in knowledge may lead to missed opportunities for developing clinical guidelines, better tailoring of clinical guidelines and treatment protocols and developing new therapeutic agents. 43, 52 The strengths of the present study include a relatively large sample size, a focus on an understudied ancestral group, use of state-of-the-art SNP microarrays and imputation to an African enriched reference panel providing an unparalleled comprehensive opportunity to test millions of common SNPs across African genomes. A potential limitation is that SNPs with small effect sizes are not detectable with the present sample size. More studies in Africans and combined analysis using meta-analytic procedures would overcome this limitation.
In summary, we report a genome-wide analysis of T2D in sub-Saharan Africa in a sample of over 5,000 individuals. The major findings include confirmation of TCF7L2 as genome-wide significant and identification of ZRANB3 as a novel T2D locus. Functional experiments in zebrafish suggest that ZRANB3 is important in beta cell proliferation and thereby the capacity of the pancreas to respond to insulinogenic stimuli.
Subjects and Methods
Ethics statement
All human research was conducted according to the Declaration of Helsinki. The study protocol was approved by the institutional ethics review board of each participating institution. Written informed consent was obtained from each participant prior to enrolment.
Study participants
Study participants are from the Africa America Diabetes mellitus (AADM) study. 3, 6 This is a study of the genetic epidemiology of T2D in Africa that enrolled participants from Nigeria, Ghana, and Kenya. The study eligibility criteria and enrollment procedures have been described in detail elsewhere. 3, 4, 6 Briefly, participants were Africans enrolled through major medical centers in Nigeria (Ibadan, Lagos and Enugu), Ghana (Accra and Kumasi) and Kenya 
Genotyping and Imputation
The 5,231 samples were genotyped on two platforms: 1,808 samples were genotyped using 
Association analysis
Association analysis was done using the GMMAT (Generalized linear Mixed Model Association
Test) R package 54 , a software package for association tests based on generalized linear mixed models. We computed principal components (PCs) using an LD-pruned subset of SNPs (Supplementary Figure 1) . Similar to our previous study 4 , we found that the first three PCs were significant and were therefore included in downstream analyses. To account for relatedness between individuals in the sample, we computed a genetic relatedness matrix (GRM) using GEMMA (the Genome-wide Efficient Mixed Model Association algorithm) 55 .
Association testing for T2D was done using the mixed logistic model as implemented in
GMMAT. This is a score test which was done with the imputed genotype dosages with age, gender, BMI, the GRM and the first three PCs as covariates.
Statistical power estimates
The power of the study for discovery was estimated using Quanto 56 and assuming an α of 5 X 10 -8 . For a variant with a minor allele frequency (MAF) of 0.05, the study has 80% power to detect a genetic risk ratio (GRR) of 1.7 and 94% power to detect a GRR of 1.8. For a variant with MAF of 0.10, the study has 82% power to detect a GRR of 1.5 and 98% power to detect a GRR of 1.6.
eQTL annotation of ZRANB3
For eQTL annotation of the genome-wide significant ZRANB3 SNPs, we utilized data from the Framingham Heart Study (FHS) eQTL Study 38 accessed via the NCBI Molecular QTL Browser (see Web Resources). This is a microarray-based genome-wide study that analyzed both cis and trans eQTLs in whole blood samples from over 5,000 study participants. We chose this database because till date it is the largest, single site study of both cis-eQTLs and transeQTLs. First, we used the haplotype block definition method of Gabriel et al 57 to construct haplotypes around the two genome-wide significant SNPs, resulting in an 18.7 kb haplotype block around 2:136064024 and a 16.8 kb haplotype bock around 2:136019729. Next, we retrieved significant eQTLs in these two haplotype blocks from the FHS-eQTL Study and identified cis-as well as trans-eQTL SNP-gene pairs. We then overlaid the gene lists from the retrieved eQTL data on the list of significant associations with T2D in the NHGRI-EBI GWAS Catalog. To provide finer resolution, we annotated the SNPs flanking each genome-wide significant ZRANB3 SNP for eQTLs.
Meta-analysis
Given the paucity of genome-wide data on Africans characterized for T2D, we conduct a metaanalysis of our GWAS with an African ancestry dataset: a GWAS of African American samples for T2D (n=8,599) conducted on African American participants from five studies (the Atherosclerosis Risk in Communities (ARIC), the Cleveland Family Study (CFS), the Howard University Family Study (HUFS), Jackson Heart Study (JHS) and Multi-Ethnic Study of Atherosclerosis (MESA) retrieved under controlled access from dbGAP. We used a fixed effects model with inverse weighting of effect sizes as implemented in METAL 58 with double genome inflation correction. As a check, we utilized a meta-analysis method that allows for heterogeneity of effects as implemented in MetaSoft 59 and obtained essentially the same findings (thus, results from METAL are presented). For trans-ethnic meta-analysis, we conduct a meta-analysis for T2D with data from the present GWAS, the African American studies and the DIAGRAM meta-analysis of 13 cohorts imputed from the GoT2D integrated haplotype reference panel 8 .
Transferability of established type 2 diabetes loci
We looked for evidence of transferability of established T2D loci reported in the literature and curated with the aid of the NHGRI-EBI GWAS Catalog and updated with the latest metaanalysis studies. We considered a p value < 0.05 associated with a SNP with the same direction of effect as evidence of transferability. Where the exact SNP was not present or did not show significant association in our dataset, we examined all SNPs with LD r 2 > 0.3 and within + 250kb of the reported index SNP for association with T2D. Nominal association p values were adjusted for the total number of SNPs within the region using the method of effective degrees of freedom. 60, 61 A locus was considered to show local replication if it had at least one of the tested SNPs with adjusted association p-value < 0.05.
Zebrafish lines
Experiments were carried out using Tg(insa:mCherry). 62 Adult zebrafish were housed and naturally mated according to standard protocol. All zebrafish work was conducted in accordance with University of Maryland IACUC guidelines.
Morpholino and CRISPR/Cas9
Morpholino antisense oligonucleotides (MOs) that block splicing (SB) at the splice junction of exon 5 of zranb3 mRNA were injected into one-to two-cell stage embryos. We designed SB MO (5'-GATACTCCTGCAAAGCAAACAAACA -3'). A control non-specific MO was used (5′-CCTCTTACCTCAGTTACAATTTATA-3′). The embryos were grown at 28°C until harvesting for analyses. MO efficacy and off-target toxicity was assessed in cDNA generated from total RNA isolated from homogenates of whole 5 days post fertilization (dpf) larvae and qPCR analysis as per previously reported protocols. 9 Target sites for CRISPR were determined and designed according to previously published protocols. 9 We identified target sites within either exon 5 or exon 7 of zranb3 to which we generated sgRNAs by in vitro transcription using the following oligo sequences: 
Integrative analysis of GWAS with transcriptomic data
To identify potentially novel candidate genes and generate new hypotheses, we leveraged our GWAS to conduct functional gene set based analysis of the AADM GWAS summary statistics using publicly available transcriptomic data on selected T2D-related tissues. Gene-based functional association analytic methods capture the aggregate signals from multiple signals (eQTLs) and may be more appropriate and have more power than testing each variant separately in situations where the expression of a gene is causally related to a trait or disorder and gene expression is regulated by multiple independent eQTLs. We used EUGENE v1.3b 63 using our GWAS summary statistics as input and accounted for LD between variants with the 1000 Genomes AFR data. We restricted our analyses to adipose tissue, skeletal muscle and whole blood using precomputed eQTL reference data provided by the software authors. We used Satterthwaite's approximation to estimate the significance of the gene-based sum statistic (i.e. GCTA-fastBAT) 64 , a method which is more efficient than using simulations to estimate the gene-based sum statistic and is recommended as the default approach to estimate significance.
Data availability
The GWAS summary statistics are available at dbGap (accession pending); all relevant data are available from the authors upon request under terms consistent with the ethical controls governing the study. 
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